Shop

Author at Microdose

Microdose

At our core, we champion integrity, diversity, and objectivity, providing trusted content that unites a wide array of experts and fosters unbiased opinions, ultimately empowering the psychedelic medicine community to flourish and make a positive impact on the world.

Events

30 Apr 2022

Plant Medicine Week 2022: The Integration of Psychedelic Medicine into Mainstream Healthcare

A summary of Plant Medicine Week 2022 panel: The Integration of Psychedelic Medicine into Mainstream Healthcare...

By Microdose

Industry

29 Apr 2022

Field Trip to Split Into Two Independent Public Companies

Big news as Field Trip Health splits its operations into two separate publicly-traded companies....

By Microdose

Industry

28 Apr 2022

TRYP Therapeutics Doses First Patients in Phase 2 Psilocybin Trial

TRYP has started a Phase 2 trial to determine efficacy of psilocybin psychotherapy for the treatment of Binge Eating Disorder...

By Microdose

Industry

27 Apr 2022

Phyto Partners and Ambria Capital Launch Neurowellness VC Fund

Phyto Partners has partnered with Ambria Capital to launch a fund focused on businesses operating in and around neurowellness and brain health and the use of psychedelic compounds....

By Microdose

Join Our Newsletter for Exclusive Updates, Stories, and More

Don’t Miss

25 Apr 2022

News You Might Have Missed: April 25th, 2022

Welcome to the News You Might Have Missed, a weekly roundup of psychedelic medicine industry news items to help you catch up and stay informed....

By Microdose

Industry

22 Apr 2022

Terran Biosciences Signs Deal w Big Pharma

Terran Biosciences, a private biotech firm, has signed a licensing deal with pharmaceutical giant Sanofi (NASDAQ: SNY)....

By Microdose

Industry

20 Apr 2022

Irwin Naturals Acquires Chain of Ketamine Clinics

Irwin Naturals announced an acquisition agreement with KHC Capital Group (“Ketamine Health Centers”) and their chain of five ketamine treatment clinics in Florida....

By Microdose

Events

20 Apr 2022

PsyCap Recap: Med Plant Science

CEO Angus Taylor and co-founder Craig Stenhouse joined Microdose at the recent Psychedelic Capital event to discuss their company and its focus on nano-encapsulation, a drug delivery system that combines...

By Microdose

Events

19 Apr 2022

PsyCap Recap: Origin Therapeutics

Alfred Wong, Vice President of Investments for Origin, joined last month’s Psychedelic Capital event....

By Microdose

Follow us on social

Latest News

Trump’s Psychedelic Fast-Track Order Changes the Timeline. It Also Redraws the Competitive Map.

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

You Might Also Like

17 Dec 2025

Psychedelics in 2025: A Year of Proof, Pullback, and a Clearer Path Forward

If 2024 was the year the psychedelic field learned how hard “approval ready” really is, 2025 was the year it began behaving accordingly. The past twelve months were less about...

By Madison Roberts

26 Nov 2025

Delix Therapeutics Reports Strong Phase Ib Results

Delix Therapeutics recently announced compelling data from a Phase Ib trial of DLX-001 (zalsupindole), a non-hallucinogenic neuroplastogen. According to the company’s release, DLX-001 produced robust biomarker signals (quantitative EEG and...

By Madison Roberts

19 Nov 2025

Childhood Trauma’s Role in Men’s Substance Use Disorders

Childhood trauma leaves a deeper imprint on men’s lives than most realize—and for many, it becomes the hidden engine driving substance use disorders. Research shows that emotional abuse, physical violence,...

By Madison Roberts

19 Nov 2025

Human-Centered AI in Healthcare

Artificial intelligence is redefining modern healthcare, offering powerful tools that enhance diagnosis, expedite drug discovery, and enable truly personalized treatment. As health systems struggle with rising costs, aging populations, and...

By Madison Roberts

16 Oct 2025

Enveric Biosciences Doubles Down on IP Strength as Psychedelic Biotech Sector Heats Up

As Big Pharma makes billion-dollar bets in the evolving landscape of neuropsychiatric therapeutics, Enveric Biosciences (NASDAQ: ENVB) is carving out a formidable position — not by chasing headlines, but by...

By Madison Roberts

15 Oct 2025

The IP Battle Behind the $1.2B Psychedelic Acquisition—and Why Enveric Biosciences Is a Name to Watch

Take Enveric Biosciences (NASDAQ: ENVB), a company that’s been flying under the radar while building an IP fortress around a novel class of non-hallucinogenic neuroplastogens. Now, that fortress is being...

By Madison Roberts
WordPress Ads
No Result
View All Result

© 2026 JNews - Premium WordPress news & magazine theme by Jegtheme.